LD-2 disclosure · 3rd Quarter - Report
EISAI INC.
via EISAI INC.
Client
- Name
- EISAI INC.
- Location
- New Jersey · United States of America
Registrant
- Firm
- EISAI INC.
- Description
- Pharmaceutical development, manufacturing and distribution -- Health Care
- Location
- Nutley, New Jersey, United States of America
Lobbying activities
3 issuesHealth Issues
Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; Prescription Drug User Fee Act (PDUFA) reauthorization; The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).
Lobbyistsms TRICIA BROOKS
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Access to medicines in Medicare; CMS NCD for Alzheimers therapies; Rebates and Medicare Part D - provisions related to the HHS-OIG Rebate Safe Harbor; Co-pay accumulators; Medicare Part D redesign proposals; Notice of Benefit and Payment Parameters; and Proposed Medicaid regulations; FY2022 Budget Reconciliation; and Inflation Reduction Act.
Lobbyistsms TRICIA BROOKS
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)
Trade (domestic/foreign)
Issues related to pharmaceutical IP and supply chain; World Trade Organization waiver of Trade-Related Aspects of Intellectual Property Rights (TRIPS); and H.R.4521, AmericaCOMPETES Act of 2022.